Evotec Secures Grant To Evaluate Antibody Drugs For COVID-19

Antibody treatments have come into focus after a study showed anti-viral drug remdesivir, one of the few drugs being used to treat people with COVID-19, has little or no impact on a patient’s chances of surviving COVID-19.

Evotec said the grant would enable its Seattle-based subsidiary Just to use its software, called Abacus, to analyse several lead candidate sequences of potent mAbs, which have been provided to the foundation by academic medical centres around the world.